Shorter TB regimens could simplify treatment

NCT ID NCT07668479

Not yet recruiting Disease control Sponsor: Public Union "Kazakhstan Association of Phthisiopulmonologists" Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether shorter, rifapentine-based treatments for tuberculosis and latent TB are safe and effective in real-world settings in Kazakhstan. It will follow 350 adults, including those with HIV, comparing a 4-month regimen to the standard 6-month one for active TB, and a 1-month regimen for latent TB. The goal is to see if these shorter options can improve cure rates and reduce side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rifapentine (combined with isoniazid, moxifloxacin, pyrazinamide, or ethambutol)
What this could lead to: If successful, this could show that shorter TB treatments work as well as standard ones, making it easier for patients to complete therapy and reducing the spread of TB.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. Side effects from the shorter regimens could still occur, and findings may not apply outside Kazakhstan.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

latent tuberculosis infection pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS TUBERCULOSIS INFECTION, LATENT TUBERCULOSIS, PULMONARY, DRUG SENSITIVE

More trials for these conditions

Other studies related to the condition(s) this trial covers.